Treating paraneoplastic hypercalcemia in dogs and cats - Veterinary Medicine
Medicine Center
DVM Veterinary Medicine Featuring Information from:


Treating paraneoplastic hypercalcemia in dogs and cats
Various tumor-related factors may lead to elevated calcium concentrations that can greatly contribute to a cancer patient's morbidity. Here's how to help alleviate the suffering associated with this common paraneoplastic syndrome.


41. Motellon JL, Jimenez FJ, de Miguel F, et al. Relationship of plasma bone cytokines with hypercalcemia in cancer patients. Clin Chim Acta 2000;302:59-68.

42. Barthez PY, Davis CR, Pool RR, et al. Multiple metaphyseal involvement of a thymic lymphoma associated with hypercalcemia in a puppy. J Am Anim Hosp Assoc 1995;31:82-85.

43. Villiers E, Dobson J. Multiple myeloma with associated polyneuropathy in a German shepherd dog. J Small Anim Pract 1998;39:249-251.

44. Matus RE, Leifer CE, MacEwen EG, et al. Prognostic factors for multiple myeloma in the dog. J Am Vet Med Assoc 1986;188:1288-1292.

45. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991;41(Suppl 3):14-22.

46. Puschett JB. Pharmacological classification and renal actions of diuretics. Cardiology 1994;84(Suppl 2):4-13.

47. Adin DB, Taylor AW, Hill RC, et al. Intermittent bolus injection versus continuous infusion of furosemide in normal adult greyhound dogs. J Vet Intern Med 2003;17:632-636.

48. Price GS, Page RL, Fischer BM, et al. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991;5:259-262.

49. Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996;22:265-287.

50. Tenta R, Sourla A, Lembessis P, et al. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res 2006;26(1A):283-291.

51. Milner RJ, Farese J, Henry CJ, et al. Bisphosphonates and cancer. J Vet Intern Med 2004;18:597-604.

52. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997;80(8 Suppl):1652-1660.

53. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-465.

54. Rumbeiha WK, Fitzgerald SD, Kruger JM, et al. Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs. Am J Vet Res 2000;61:9-13.

55. Rumbeiha WK, Kruger JM, Fitzgerald SF, et al. Use of pamidronate to reverse vitamin D3-induced toxicosis in dogs. Am J Vet Res 1999;60:1092-1097.

56. Hostutler RA, Chew DJ, Jaeger JQ, et al. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. J Vet Intern Med 2005;19:29-33.

57. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.

58. Rosol T, Chew D, Hammer A. Effect of mithramycin on hypercalcemia in dogs. J Am Anim Hosp Assoc 1994;30:244-250.


Click here